Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 10,540 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital Disorders Clear all
Completed Phase 2 Interventional Results available

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

NCT01607879
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
60 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

NCT00001062
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 21, 2026, 4:21 PM EDT
Terminated Phase 4 Interventional Results available

Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders

NCT01373918
View directory record Official record
Conditions
Cholestasis
Interventions
Intralipid
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Minute to 5 Days
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Not applicable Interventional

The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.

NCT04691323
View directory record Official record
Conditions
Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C
Interventions
HU-Go app
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 4:21 PM EDT
Terminated Phase 3 Interventional

Type of Material in Repair of Congenital Diaphragmatic Hernia

NCT00257946
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
Repair of CDH w/SIS Gold, Repair of CDH w/Alloderm
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 2 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 21, 2026, 4:21 PM EDT
Recruiting No phase listed Observational

Lymphatic Anomalies Registry for the Assessment of Outcome Data

NCT02399527
View directory record Official record
Conditions
Lymphatic Malformation, Generalized Lymphatic Anomaly (GLA), Central Conducting Lymphatic Anomaly, CLOVES Syndrome, Gorham-Stout Disease ("Disappearing Bone Disease"), Blue Rubber Bleb Nevus Syndrome, Kaposiform Lymphangiomatosis, Kaposiform Hemangioendothelioma/Tufted Angioma, Klippel-Trenaunay Syndrome, Lymphangiomatosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 4:21 PM EDT
Active, not recruiting No phase listed Observational

Longitudinal Evaluation of Active-Duty Personnel with Accessory Pathways (LEAD-AP)

NCT06798961
View directory record Official record
Conditions
Cardiac Death, Cardiac Death, Sudden, Wolf Parkinson White Syndrome
Interventions
Ablation, Standard of care without ablation
Procedure
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

NCT04486742
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Itch CBT
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
8 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 21, 2026, 4:21 PM EDT
Completed No phase listed Observational

Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)

NCT00417846
View directory record Official record
Conditions
Maculopathy, Age-Related, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Beverly Hills, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2009 · Synced Oct 21, 2026, 4:21 PM EDT
Completed No phase listed Observational

Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

NCT02998710
View directory record Official record
Conditions
Homocystinuria Due to CBS Deficiency
Interventions
Not listed
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 4:21 PM EDT
Completed No phase listed Observational

Cardiac Magnetic Resonance in Children With Muscular Dystrophy

NCT01081080
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 21, 2026, 4:21 PM EDT
Completed No phase listed Observational

Myotubular Myopathy Genetic Testing Study

NCT01817946
View directory record Official record
Conditions
Myotubular Myopathy
Interventions
Genetic Testing
Other
Lead sponsor
Cure CMD
Other
Eligibility
30 Days and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 21, 2026, 4:21 PM EDT
No Longer Available No phase listed Expanded access

Extension Study of Drisapersen in DMD Subjects

NCT02636686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Drisapersen
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 21, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair

NCT02575846
View directory record Official record
Conditions
Gastroschisis
Interventions
Enteral Intake - Human Milk, Enteral Intake - Formula
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
2 Hours to 48 Hours
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 21, 2026, 4:21 PM EDT
Completed No phase listed Observational

SPY Imaging System: Its Role in Pediatric Cardiac Surgery

NCT00446927
View directory record Official record
Conditions
Cardiopulmonary Bypass, Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Early Phase 1 Interventional Results available

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

NCT01275586
View directory record Official record
Conditions
Neurofibromatosis, NF1, Neurofibromas
Interventions
Tasigna
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Not applicable Interventional

Non-Invasive Neurally Adjusted Ventilatory Assist (NAVA) Prone vs Supine in Premature Infants

NCT05968586
View directory record Official record
Conditions
Neonatal Oxygen Desaturation, Premature, Ventilator Lung; Newborn, Apnea of Prematurity
Interventions
Body positioning
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Minute to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

NCT00883090
View directory record Official record
Conditions
Factor XIII Deficiency
Interventions
FXIII Concentrate (Human)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Dothan, Alabama • Orange, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

NCT00020046
View directory record Official record
Conditions
Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 21, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

NCT01467427
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 12 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 4:21 PM EDT
Active, not recruiting Not applicable Interventional

Pediatric Powered Wheelchair Standing Devices: An Exploratory Study

NCT05117827
View directory record Official record
Conditions
Cerebral Palsy, Spinal Muscular Atrophy, Spinal Cord Injuries, Spina Bifida, Development Delay, Genetic Disease
Interventions
Power Wheelchair Standing Device
Device
Lead sponsor
Grand Valley State University
Other
Eligibility
5 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 4:21 PM EDT
Recruiting Phase 4 Interventional

A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab

NCT06145373
View directory record Official record
Conditions
Hemophilia A
Interventions
Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Los Angeles, California • Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 4:21 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 21, 2026, 4:21 PM EDT